Department of Urology, VU University Medical Center, Amsterdam, The Netherlands.
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Epigenomics. 2018 May;10(5):673-687. doi: 10.2217/epi-2017-0156. Epub 2018 Apr 25.
Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.
PATIENTS & METHODS: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.
A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.
Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.
已经有几种尿甲基化标志物（hmDNA）被描述用于膀胱癌（BC）的检测，但没有一种能够替代膀胱镜检查。我们系统地回顾和评估了目前关于用于 BC 诊断的尿 hmDNA 标志物的文献。
我们按照系统评价和荟萃分析的首选报告项目指南，对截至 2017 年 2 月的 PubMed、EMBASE.com 和 The Cochrane Library 进行了系统搜索。
共有 30/42 项研究比较了基因谱，其敏感性（52-100%）和特异性（0-100%）各不相同。研究之间存在很大的异质性，且大多数是病例对照研究。
报道的尿 hmDNA 用于 BC 检测的诊断准确性差异很大，且缺乏验证性研究。最近的研究表明，需要互补的标志物才能进行临床应用。
